Kazia Therapeutics (KZIA) executive reports 380K share options on Form 3

Rhea-AI Filing Summary

Kazia Therapeutics Program Director Jeremy Simpson filed an initial Form 3 reporting existing option holdings in the company. He holds options over 280,000 ordinary shares with a $0.1061 exercise price expiring on March 3, 2027, and options over 100,000 ordinary shares with a $0.6651 exercise price expiring on February 1, 2027. Footnotes explain these options were granted in 2022 and 2023 and vest in scheduled installments, reflecting compensation awards rather than new market transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Simpson Jeremy

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW AUSTRALIA 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Program Director

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Ordinary Shares Option (Right to Buy)	(1)	03/03/2027	Ordinary Shares	280,000	$0.1061(2)	D
Ordinary Shares Option (Right to Buy)	(3)	02/01/2027	Ordinary Shares	100,000	$0.6651(2)	D

Explanation of Responses:

1. The Ordinary Shares subject to the option ("OS option") vest in four equal semi-annual installments beginning on March 3, 2023, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on March 3, 2023.

2. The exercise price is reported in U.S. dollars and reflects the conversion from AUD to USD at an exchange rate of 0.7075 USD per 1.00 AUD as of March 18, 2026.

3. The Ordinary Shares subject to the OS option vest in four equal annual installments beginning on February 1, 2022, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The OS option was granted on February 1, 2022.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeffrey Bonacorda, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Jeremy Simpson report in his Form 3 for KZIA?

Jeremy Simpson reports existing options to buy Kazia Therapeutics ordinary shares. These include 280,000 shares at $0.1061 and 100,000 shares at $0.6651, representing prior equity compensation awards that vest over time rather than new share purchases or sales.

How many Kazia Therapeutics (KZIA) shares are covered by Simpson’s options?

His reported options cover 380,000 Kazia Therapeutics ordinary shares in total. This consists of 280,000 underlying shares tied to one option grant and 100,000 underlying shares tied to a second grant, both held directly as part of his compensation package.

What are the exercise prices and expirations of Simpson’s KZIA options?

One option grant has a $0.1061 exercise price and expires on March 3, 2027. The other has a $0.6651 exercise price and expires on February 1, 2027. Both are options on Kazia Therapeutics ordinary shares held as derivative positions.

How do Jeremy Simpson’s KZIA options vest over time?

The 280,000-share option vests in four equal semi-annual installments starting March 3, 2023. The 100,000-share option vests in four equal annual installments starting February 1, 2022. Each vesting date requires Simpson’s continuous service with Kazia Therapeutics through that date.

Do Jeremy Simpson’s reported KZIA holdings indicate recent buying or selling?

The filing lists holdings, not recent trades, and shows no explicit buy or sell transactions. It discloses outstanding options previously granted as compensation, with vesting schedules and exercise prices, providing a snapshot of his existing derivative position in Kazia Therapeutics.